← Eichor
Condition: Toripalimab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Toripalimab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Nega
Phase 2 · 2 location(s) · Fudan University · NCT06636981Toripalimab With Chemotherapy for Sinus Cancer
Phase 2 · 2 location(s) · Glenn J. Hanna · NCT06940180HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05628038ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06426511Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06705127Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Nanjing Immunophage Biotech Co., Ltd · NCT07508761Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07177794De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyng
NA · 1 location(s) · Sun Yat-sen University · NCT06313450LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07325539This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07111832Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06323382To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvan
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06389006A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06371274Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Phase 2 · 4 location(s) · Sun Yat-sen University · NCT03810339A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So
Phase 1 · 30 location(s) · Coherus Oncology, Inc. · NCT06657144Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant
EARLY_Phase 1 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05579275Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Phase 2 · 2 location(s) · Xijing Hospital · NCT069144409MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Phase 2 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT07314723A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Phase 2 · 5 location(s) · Abbisko Therapeutics Co, Ltd · NCT06111274A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Tr
Phase 1/Phase 2 · 1 location(s) · Junjie Hang · NCT07040228Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06525428Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
Phase 2 · 1 location(s) · Shanghai Pudong Hospital · NCT07106034A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT04365036Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03926338Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Phase 3 · 1 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT05342194Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Ve
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07706985
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.